DC-Y13-27
Based on 6 publication(s) in Google Scholar
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.52%
- Formel: C14H10N2O2S
- Molecular Weight:270.31
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Differentiation Inducing Compound Library
HY-L038
-
Pyroptosis Compound Library
HY-L059
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Autoimmune Disease Compound Library
HY-L156
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
Publications Citing Use of MedChemExpress (MCE) DC-Y13-27
More- Mol Cell. 2023 Dec 7;83(23):4334-4351.e7. [Abstract]
- Phytomedicine. 2026 Jul:156:158239. [Abstract]
- Diabetologia. 2025 Jun;68(6):1335-1351. [Abstract]
- Environ Int. 2024 Feb:184:108493. [Abstract]
- Int J Biol Macromol. 2026 Jun:367:152621. [Abstract]
- Cell Mol Life Sci. 2024 Dec 3;81(1):477. [Abstract]
Customer Validation & Images
-
Cell Imaging/Staining
-
WB
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
Biologische Aktivität
|
YTHDF2 37.9 μM (Kd) |
FOXO3 |
MMP-1 |
MMP3 |
MMP-7 |
MMP9 |
IL-1β |
DC-Y13-27 binds to YTHDF2 with a binding constant (KD) of 37.9 μM[1].
DC-Y13-27 (20-40 μM; 6 h) co-treated with H2O2 reduces YTHDF2 expression, restores FOXO3 and TIMP1 protein levels, and decreases MMP1/3/7/9 expression in NP and AF cells[2].
DC-Y13-27 (24 h) inhibits cell proliferation, increases LDH release and IL-1β secretion, and induces pyroptosis in MDA-MB-231 and BT-549 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
DC-Y13-27 (5 mg/kg; s.c.; every 5 days; 12 weeks) alleviates intervertebral disc degeneration in aged mice and H2O2-induced IDD models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (8 weeks old initially) with aged or H2O2-induced IDD[2].
-
Dosage:5 mg/kg
-
Administration:Subcutaneous injection near lumbar discs, every 5 days, for 12 weeks
-
Result:Reduced disc degeneration, increased FOXO3 and TIMP1 expression, and decreased MMP1/3/7/9 activity in IVD tissues.
Chemical Information
-
Appearance Solid
-
Molecular Weight 270.31
-
Formel C14H10N2O2S
-
Color Yellow to orange
-
SMILES
N#C/C(C(N)=O)=C\C1=CC=C(C2=CC(O)=CC=C2)S1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Mol Cell
EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma. [Abstract]2023 Dec 7;83(23):4334-4351.e7. PMID: 37979586 -
Phytomedicine
Dihydroartemisinin, a novel YTHDF2 inhibitor, alleviates rheumatoid arthritis by suppressing neutrophil extracellular traps via an autophagy-dependent pathway. [Abstract]2026 Jul:156:158239. PMID: 42068879 -
Diabetologia
MAP4K4 aggravates microvascular anomalies in diabetic retinopathy in a YTHDF2-dependent manner. [Abstract]2025 Jun;68(6):1335-1351. PMID: 40072537 -
Environ Int
HIF-1α/m6A/NF-κB/CCL3 axis-mediated immunosurveillance participates in low level benzene-related erythrohematopoietic development toxicity. [Abstract]2024 Feb:184:108493. PMID: 38350257 -
Int J Biol Macromol
Hypoxia-mediated epigenetic silencing of YTHDF2 promotes endometriosis progression via the NFE2L1-NF-κB axis. [Abstract]2026 Jun:367:152621. PMID: 42162597 -
Cell Mol Life Sci
YTHDF2-dependent m6A modification of FOXO3 mRNA mediates TIMP1 expression and contributes to intervertebral disc degeneration following ROS stimulation. [Abstract]2024 Dec 3;81(1):477. PMID: 39625652
DC-Y13-27 purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2024 Dec 3;81(1):477. [Abstract]
Changes in intracellular ROS levels in NP cells following treatment with H2O2 (0 and 150 µM) and DC-Y13-27 (0, 20, and 40 µM) for 6 h. ROS levels were quantified using DCFH-DA staining.
DC-Y13-27 purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2024 Dec 3;81(1):477. [Abstract]
Protein expression levels of YTHDF2, FOXO3, Med1, CBP, TIMP1, MMP1, MMP3, MMP7, and MMP9 in NP cells after treatment with H2O2 and DC-Y13-27 (0-40 µM, 6 h).
DC-Y13-27 purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2024 Dec 3;81(1):477. [Abstract]
RIP assay to detect FOXO3 mRNA association with YTHDF2 in NP cells treated with H2O2 and DC-Y13-27 (0-40 µM, 6 h), using IgG and anti-YTHDF2 antibodies.
DC-Y13-27 purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2024 Dec 3;81(1):477. [Abstract]
Schematic representation of DC-Y13-27 administration in aged mice. ROS levels in lumbar IVDs from young mice (8 weeks old), 52-week-old mice treated with PBS or DC-Y13-27 (5 mg/kg).
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (369.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (9.25 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Wang L, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 May 15:S1535-6108(23)00163-0. [Content Brief]
[2]. Wang F, et al. YTHDF2-dependent m6A modification of FOXO3 mRNA mediates TIMP1 expression and contributes to intervertebral disc degeneration following ROS stimulation. Cell Mol Life Sci. 2024 Dec 3;81(1):477. [Content Brief]
[3]. Shuai Y, et al. The N6-methyladenosine writer METTL3 promotes breast cancer progression through YTHDF2-dependent posttranscriptional silencing of GSDMD. Apoptosis. 2025 Feb;30(1-2):226-238. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6995 mL | 18.4973 mL | 36.9946 mL | 92.4864 mL |
| 5 mM | 0.7399 mL | 3.6995 mL | 7.3989 mL | 18.4973 mL | |
| 10 mM | 0.3699 mL | 1.8497 mL | 3.6995 mL | 9.2486 mL | |
| 15 mM | 0.2466 mL | 1.2332 mL | 2.4663 mL | 6.1658 mL | |
| 20 mM | 0.1850 mL | 0.9249 mL | 1.8497 mL | 4.6243 mL | |
| 25 mM | 0.1480 mL | 0.7399 mL | 1.4798 mL | 3.6995 mL | |
| 30 mM | 0.1233 mL | 0.6166 mL | 1.2332 mL | 3.0829 mL | |
| 40 mM | 0.0925 mL | 0.4624 mL | 0.9249 mL | 2.3122 mL | |
| 50 mM | 0.0740 mL | 0.3699 mL | 0.7399 mL | 1.8497 mL | |
| 60 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5414 mL | |
| 80 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 1.1561 mL | |
| 100 mM | 0.0370 mL | 0.1850 mL | 0.3699 mL | 0.9249 mL |
DC-Y13-27 Related Classifications
HY-154919 Related Classifications
Powered by Bioz